Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).
Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.
CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.
The gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $9.5 million. The Company intends to use the net proceeds ...
The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...
Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...
The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...
Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL).Stay Ahead of the Market:Discover ...
Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...
The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...
Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback